Related Experiment Video
Updated: Jun 24, 2025
A Preclinical Murine Model of Hepatic Metastases
Published on: September 27, 2014
Establishment of a Transplantation Model of PDAC-Derived Liver Metastases
Benedetta Ferrara1, Erica Dugnani1, Antonio Citro1
1Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Background:
The highly metastatic nature of pancreatic ductal adenocarcinoma (PDAC) and the difficulty to achieve favorable patient outcomes emphasize the need for novel therapeutic solutions. For preclinical evaluations, genetically engineered mouse models are often used to mimic human PDAC but frequently fail to replicate synchronous development and metastatic spread. This study aimed to develop a transplantation model to achieve synchronous and homogenous PDAC growth with controlled metastatic patterns in the liver.
Methods:
To generate an orthotopic PDAC model, the DT6606 cell line was injected into the pancreas head of C57BL/6 mice, and their survival was monitored over time. To generate a heterotopic transplantation model, growing doses of three PDAC cell lines (DT6606, DT6606lm, and K8484) were injected into the portal vein of mice. Magnetic resonance imaging (MRI) was used to monitor metastatic progression, and histologic analysis was performed.
Results:
Orthotopically injected mice succumbed to the tumor within an 11-week period (average survival time, 78.2 ± 4.45 days). Post-mortem examinations failed to identify liver metastasis. In the intraportal model, 2 × 105 DT6606 cells resulted in an absence of liver metastases by day 21, whereas 5 × 104 DT6606lm cells and 7 × 104 K8484 cells resulted in steady metastatic growth. Higher doses caused significant metastatic liver involvement. The use of K8484 cells ensured the growth of tumors closely resembling the histopathologic characteristics of human PDAC.
Conclusions:
This report details the authors' efforts to establish an "optimal" murine model for inducing metastatic PDAC, which is critical for advancing our understanding of the disease and developing more effective treatments.
Insights
Researchers developed a new mouse model for pancreatic ductal adenocarcinoma (PDAC) metastasis. This model allows for controlled liver metastasis, crucial for testing new pancreatic cancer treatments.
Area of Science:
- Oncology
- Preclinical Research
- Animal Models
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is highly metastatic, necessitating new therapies.
- Current mouse models often fail to replicate human PDAC's metastatic spread.
- A need exists for models that mimic synchronous tumor development and metastasis.
Purpose of the Study:
- To develop an optimal murine model for inducing metastatic PDAC.
- To achieve synchronous and homogenous PDAC growth.
- To establish controlled metastatic patterns in the liver for preclinical research.
Main Methods:
- Orthotopic injection of DT6606 cells into mouse pancreas heads.
- Intraportal vein injection of PDAC cell lines (DT6606, DT6606lm, K8484) for heterotopic models.
- Monitoring tumor growth and liver metastasis using MRI and histologic analysis.
Main Results:
- Orthotopic tumors led to death within 11 weeks, without liver metastasis.
- Intraportal injection of DT6606lm and K8484 cells induced progressive liver metastasis.
- K8484 cells generated tumors histopathologically similar to human PDAC.
- Higher cell doses correlated with increased liver metastatic burden.
Conclusions:
- A novel transplantation model was established for inducing metastatic PDAC in mice.
- This model facilitates the study of PDAC liver metastasis.
- The model is critical for advancing understanding and developing treatments for PDAC.
